New Launch25 Jun 2025, 11:36 am
Dr. Lal PathLabs Strengthens Genomics Capabilities with Illumina’s NovaSeq X Series
AI Summary
Dr. Lal PathLabs Limited, a trusted diagnostic chain in India, has expanded its genomics capabilities by adding Illumina’s NovaSeq™ X Series to its dedicated genomics division, Genevolve. The integration of Illumina’s latest technology allows DLPL to deliver faster and more accurate genomic research insights. The NovaSeq™ X system features Illumina’s cutting-edge XLEAP-SBS™ chemistry, offering unmatched throughput, accuracy, and sustainability. Genevolve, launched in 2019, has swiftly emerged as a DNA-based center of excellence, and the addition of Illumina products further strengthens its position as a pioneer in next-generation sequencing (NGS).
Key Highlights
- Dr. Lal PathLabs Limited expands its genomics capabilities with Illumina’s NovaSeq™ X Series.
- The NovaSeq™ X system features Illumina’s cutting-edge XLEAP-SBS™ chemistry, offering unmatched throughput, accuracy, and sustainability.
- Genevolve, launched in 2019, has swiftly emerged as a DNA-based center of excellence.
- The addition of Illumina products further strengthens Genevolve’s position as a pioneer in next-generation sequencing (NGS).
- Illumina aims to democratize access to sequencing technologies in India.